Publication date: October 2020Source: Biomedicine & Pharmacotherapy, Volume 130Author(s): Zhe Wu, Yaqiong Zhan, Li Wang, Jiepeng Tong, Li Zhang, Mengjia Lin, Xuehang Jin, Lushun Jiang, Yan Lou, Yunqing Qiu
Publication date: October 2020Source: Biomedicine & Pharmacotherapy, Volume 130Author(s): P.C. de Souza, G.F.S. Fernandes, L.B. Marino, C.M. Ribeiro, P.B. da Silva, M. Chorilli, C.S.P. Silva, F.A. Resende, M.C. Solcia, R.A. de Grandis, C.A.S. Costa, S.H. Cho, Y. Wang, S.G. Franzblau, J.L. dos Santos, F.R. Pavan
Publication date: October 2020Source: Biomedicine & Pharmacotherapy, Volume 130Author(s): Mansour A. Alghamdi, Abdelaziz M. Hussein, Laith N. AL-Eitan, Eman Elnashar, Ahmed Elgendy, Asim M. Abdalla, Seham Ahmed, Wael A. Khalil
Publication date: October 2020Source: Biomedicine & Pharmacotherapy, Volume 130Author(s): Qiongge Hu, Yunxiang Zhou, Shijie Wu, Wei Wu, Yongchuan Deng, Anwen Shao
Publication date: October 2020Source: Biomedicine & Pharmacotherapy, Volume 130Author(s): Yufeng Xi, Rong Ju, Yujia Wang
Mark above section as read
Publication date: Available online 3 August 2020Source: BrachytherapyAuthor(s): Nelson N. Stone, Vassilios M. Skouteris, Barry S. Rosenstein, Richard G. Stock
Mark above section as read
Summary Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular carcinoma (HCC) patients after the phase III RESORCE trial. This study analyzed real-world data to assess the clinical effectiveness and safety of regorafenib compared to the RESORCE trial. Methods This multicenter cohort study included HCC patients treated with regorafenib after sorafenib (n = 133). We evaluated the time to progression (TTP), progression-free survival (PFS),...
Mark above section as read
Evaluation of interplay and organ motion effects by means of 4D dose reconstruction and accumulation
Pencil beam scanned proton therapy (PBS PT) treatments of intrathoracic targets are associated with significant uncertainty. Treatment quality may be compromised by setup errors, range uncertainties, respiratory motion baseline shifts, anatomical changes, delivery inaccuracies and motion of various sources (e.g. respiration, cardiac motion, swallowing, etc.). More specifically, the relative motion between a thoracic target volume and the scanning proton beam can cause deviation of the delivered dose...
Mark above section as read
Publication date: October 2020Source: International Immunopharmacology, Volume 87Author(s): Kun Yi, Qian Zhu, Yu-Kang Kuang, Si-Cong Jiang, Hao Hu
Publication date: October 2020Source: International Immunopharmacology, Volume 87Author(s): Xin Liu, Jiaqi Wu, Ning Wang, Lin Xia, Shijun Fan, Yongling Lu, Xiaoli Chen, Shenglan Shang, Yongjun Yang, Qianying Huang, Qian Chen, Hong Zhou, Jiang Zheng
Mark above section as read
Publication date: Available online 4 August 2020Source: Journal of Bodywork and Movement TherapiesAuthor(s): Weverton Rufo-Tavares, Claudio Andre Barbosa Lira, Marilia Santos Andrade, Carla Zimerer, André Soares Leopoldo, Karine Jacon Sarro, Paulo Gentil, Pantelis Theodoros Nikolaidis, Thomas Rosemann, Beat Knechtle, Rodrigo Luiz Vancini
Mark above section as read
Publication date: September 2020Source: Photodiagnosis and Photodynamic Therapy, Volume 31Author(s): Ibrahim H. Aboughaleb, Mohamed Hisham Aref, Yasser H. El-Sharkawy
Mark above section as read
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου